bims-minfam Biomed News
on Inflammation and metabolism in ageing and cancer
Issue of 2024–10–20
three papers selected by
Ayesh Seneviratne, McMaster University
  1. LGBTQ older adults deserve safe and affirming housing.
  2. Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.
  3. Inflammation in myelodysplastic syndrome pathogenesis.
  1. Nat Aging. 2024 Oct 15.
    LGBTQ older adults deserve safe and affirming housing.
    Philippe Saad.
      
    DOI:  https://doi.org/10.1038/s43587-024-00739-4
  2. Aging (Albany NY). 2024 Oct 16. 16
    Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.
    Yu-Xuan Lyu, Qiang Fu, Dominika Wilczok, Kejun Ying, Aaron King, Adam Antebi, Aleksandar Vojta, Alexandra Stolzing, Alexey Moskalev, Anastasia Georgievskaya, Andrea B Maier, Andrea Olsen, Anja Groth, Anna Katharina Simon, Anne Brunet, Aisyah Jamil, Anton Kulaga, Asif Bhatti, Benjamin Yaden, Bente Klarlund Pedersen, Björn Schumacher, Boris Djordjevic, Brian Kennedy, Chieh Chen, Christine Yuan Huang, Christoph U Correll, Coleen T Murphy, Collin Y Ewald, Danica Chen, Dario Riccardo Valenzano, Dariusz Sołdacki, David Erritzoe, David Meyer, David A Sinclair, Eduardo Nunes Chini, Emma C Teeling, Eric Morgen, Eric Verdin, Erik Vernet, Estefano Pinilla, Evandro F Fang, Evelyne Bischof, Evi M Mercken, Fabian Finger, Folkert Kuipers, Frank W Pun, Gabor Gyülveszi, Gabriele Civiletto, Garri Zmudze, Gil Blander, Harold A Pincus, Joshua McClure, James L Kirkland, James Peyer, Jamie N Justice, Jan Vijg, Jennifer R Gruhn, Jerry McLaughlin, Joan Mannick, João Passos, Joseph A Baur, Joe Betts-LaCroix, John M Sedivy, John R Speakman, Jordan Shlain, Julia von Maltzahn, Katrin I Andreasson, Kelsey Moody, Konstantinos Palikaras, Kristen Fortney, Laura J Niedernhofer, Lene Juel Rasmussen, Liesbeth M Veenhoff, Lisa Melton, Luigi Ferrucci, Marco Quarta, Maria Koval, Maria Marinova, Mark Hamalainen, Maximilian Unfried, Michael S Ringel, Milos Filipovic, Mourad Topors, Natalia Mitin, Nawal Roy, Nika Pintar, Nir Barzilai, Paolo Binetti, Parminder Singh, Paul Kohlhaas, Paul D Robbins, Paul Rubin, Peter O Fedichev, Petrina Kamya, Pura Muñoz-Canoves, Rafael de Cabo, Richard G A Faragher, Rob Konrad, Roberto Ripa, Robin Mansukhani, Sabrina Büttner, Sara A Wickström, Sebastian Brunemeier, Sergey Jakimov, Shan Luo, Sharon Rosenzweig-Lipson, Shih-Yin Tsai, Stefanie Dimmeler, Thomas A Rando, Tim R Peterson, Tina Woods, Tony Wyss-Coray, Toren Finkel, Tzipora Strauss, Vadim N Gladyshev, Valter D Longo, Varun B Dwaraka, Vera Gorbunova, Victoria A Acosta-Rodríguez, Vincenzo Sorrentino, Vittorio Sebastiano, Wenbin Li, Yousin Suh, Alex Zhavoronkov, Morten Scheibye-Knudsen, Daniela Bakula.
      The recent unprecedented progress in ageing research and drug discovery brings together fundamental research and clinical applications to advance the goal of promoting healthy longevity in the human population. We, from the gathering at the Aging Research and Drug Discovery Meeting in 2023, summarised the latest developments in healthspan biotechnology, with a particular emphasis on artificial intelligence (AI), biomarkers and clocks, geroscience, and clinical trials and interventions for healthy longevity. Moreover, we provide an overview of academic research and the biotech industry focused on targeting ageing as the root of age-related diseases to combat multimorbidity and extend healthspan. We propose that the integration of generative AI, cutting-edge biological technology, and longevity medicine is essential for extending the productive and healthy human lifespan.
    Keywords:  artificial intelligence; biotechnology; healthy longevity
    DOI:  https://doi.org/10.18632/aging.206135
  3. Semin Hematol. 2024 Sep 21. pii: S0037-1963(24)00107-0. [Epub ahead of print]
    Inflammation in myelodysplastic syndrome pathogenesis.
    Juan Jose Rodriguez-Sevilla, Simona Colla.
      Inflammation is a key driver of the progression of preleukemic myeloid conditions, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS), to myelodysplastic syndromes (MDS). Inflammation is a critical mediator in the complex interplay of the genetic, epigenetic, and microenvironmental factors contributing to clonal evolution. Under inflammatory conditions, somatic mutations in TET2, DNMT3A, and ASXL1, the most frequently mutated genes in CHIP and CCUS, induce a competitive advantage to hematopoietic stem and progenitor cells, which leads to their clonal expansion in the bone marrow. Chronic inflammation also drives metabolic reprogramming and immune system deregulation, further promoting the expansion of malignant clones. This review underscores the urgent need to fully elucidate the role of inflammation in MDS initiation and highlights the potential of the therapeutical targeting of inflammatory pathways as an early intervention in MDS.
    Keywords:  Clonal cytopenia of undetermined significance; Clonal hematopoiesis of indeterminate potential; Hematopoietic stem cells; Inflammation; Myelodysplastic syndromes
    DOI:  https://doi.org/10.1053/j.seminhematol.2024.09.005
This page is being maintained by Thomas Krichel. It was last updated on 2025‒08‒04 at 11:39.